{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:39:27Z","timestamp":1786991967026,"version":"build-2736575974"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jdcr.2024.12.022","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:09:09Z","timestamp":1735646949000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication"],"prefix":"10.1016","volume":"57","author":[{"given":"Travis C.","family":"Frantz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kirwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Brahe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2024.12.022_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jaad.2017.08.046","article-title":"Drug-associated hidradenitis suppurativa: a systematic review of case reports","volume":"78","author":"Frew","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jdcr.2024.12.022_bib2","series-title":"A Comprehensive Guide to Hidradenitis Suppurativa","first-page":"105","article-title":"Genetics and epigenetics of hidradenitis suppurativa","author":"Myers","year":"2022"},{"issue":"3","key":"10.1016\/j.jdcr.2024.12.022_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11684-019-0722-8","article-title":"Keratin 5-Cre-driven deletion of Ncstn in an acne inversa-like mouse model leads to a markedly increased IL-36a and Sprr2 expression","volume":"14","author":"Yang","year":"2020","journal-title":"Front Med"},{"issue":"14","key":"10.1016\/j.jdcr.2024.12.022_bib4","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1200\/JCO.2016.71.1994","article-title":"Clinical activity of the \u03b3-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis)","volume":"35","author":"Kummar","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jdcr.2024.12.022_bib5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jid.2017.09.051","article-title":"Hidradenitis suppurativa-like lesions associated with pharmacologic inhibition of gamma-secretase","volume":"138","author":"O\u2019Sullivan Coyne","year":"2018","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2024.12.022_bib6","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1111\/jdv.19544","article-title":"Hidradenitis suppurativa secondary to treatment with a gamma secretase inhibitor","volume":"38","author":"R\u00edos-Vi\u00f1uela","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624005137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512624005137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T12:41:30Z","timestamp":1742215290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512624005137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":6,"alternative-id":["S2352512624005137"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.022","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hidradenitis secondary to nirogacestat, a recently approved desmoid tumor medication","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2024.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}